Sir Henry Wellcome Postdoctoral Fellow
Axon degeneration is an early feature of several neurodegenerative diseases, including Parkinson's disease, motor neuron disease, multiple sclerosis and glaucoma.
I have recently been awarded a Sir Henry Wellcome postdoctoral fellowship to work in Professor Michael Coleman’s lab. My primary area of research focuses on understanding the molecular mechanisms leading to axon degeneration after injury and mitochondrial dysfunction. We aim to identify regulators of axon death and eventually study their involvement in the development of neurodegenerative disorders, with a focus on Parkinson's disease.
Recombinant protein expression
Associated News Items
Di Stefano M, Loreto A, Orsomando G, Mori V, Zamporlini F, Hulse RP, Webster J, Donaldson LF, Gering M, Raffaelli N, Coleman MP, Gilley J, Conforti L (2017), “NMN Deamidase Delays Wallerian Degeneration and Rescues Axonal Defects Caused by NMNAT2 Deficiency In Vivo” Curr Biol 27(6):784-794
Loreto A, Di Stefano M, Gering M, Conforti L (2015), “Wallerian Degeneration Is Executed by an NMN-SARM1-Dependent Late Ca(2+) Influx but Only Modestly Influenced by Mitochondria” Cell Rep 13(11):2539-52
Rossi F, Geiszler PC, Meng W, Barron MR, Prior M, Herd-Smith A, Loreto A, Lopez MY, Faas H, Pardon MC, Conforti L. (2018), “NAD-biosynthetic enzyme NMNAT1 reduces early behavioral impairment in the htau mouse model of tauopathy.” Behav Brain Res. 26;339:140-152.
Di Stefano M, Nascimento-Ferreira I, Orsomando G, Mori V, Gilley J, Brown R, Janeckova L, Vargas ME, Worrell LA, Loreto A, Tickle J, Patrick J, Webster JR, Marangoni M, Carpi FM, Pucciarelli S, Rossi F, Meng W, Sagasti A, Ribchester RR, Magni G, Coleman MP, Conforti L (2015), “A rise in NAD precursor nicotinamide mononucleotide (NMN) after injury promotes axon degeneration” Cell Death Differ 22(5):731-42
Di Pasquale G, Dicembrini I, Raimondi L, Pagano C, Egan JM, Cozzi A, Cinci L, Loreto A, Manni ME, Berretti S, Morelli A, Zheng C, Michael DG, Maggi M, Vettor R, Chiorini JA, Mannucci E, Rotella CM (2012), “Sustained exendin-4 secretion through gene therapy targeting salivary glands in two different rodent models of obesity/type 2 diabetes” PLoS One 7(7):e40074